NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.36 -0.57 (-0.70%) GOLD FUTURES
2,299.10 -3.80 (-0.17%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,249.79 -2,322.65 (-4.59%)
Incyte Corporation (INCY)
After hours:
| Previous close | 52.56 |
| Open | 50.40 |
| Bid | 52.05 x 300 |
| Ask | 52.15 x 300 |
| Day's range | 50.35 - 53.76 |
| 52-week range | 50.27 - 72.16 |
| Volume | |
| Avg. volume | 1,793,174 |
| Market cap | 11.687B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 19.64 |
| EPS (TTM) | 2.65 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 74.29 |
ZacksIncyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
- Reuters
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.
ZacksIncyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
